Search Result

Results for "

tumor imaging.

" in MedChemExpress (MCE) Product Catalog:

By Targets:	TNF Receptor (2) ADC Antibody (2) ADC Linker (4) Amino Acid Derivatives (1) Aminopeptidase (2) Apoptosis (7) Bcl-2 Family (1) Biochemical Assay Reagents (18) Bombesin Receptor (1) c-Myc (1) Cadherin (1) CaMK (1) Carbonic Anhydrase (2) CD22 (1) Cholinesterase (ChE) (1) Complement System (1) COX (1) CXCR (1) Cytochrome P450 (1) DNA/RNA Synthesis (1) Drug Derivative (3) Drug Intermediate (2) EGFR (5) Endogenous Metabolite (1) Endothelin Receptor (1) Environmental Pollutants (1) Ephrin Receptor (1) Estrogen Receptor/ERR (1) FAP (21) Ferroptosis (1) Fluorescent Dye (26) G-quadruplex (1) GLUT (1) Glycoprotein VI (1) Glycosidase (1) HDAC (1) HIF/HIF Prolyl-Hydroxylase (1) HSP (1) HSV (1) Integrin (7) Interleukin Related (4) Isotope-Labeled Compounds (2) Ligands for Target Protein for PROTAC (1) Liposome (1) Methionine Adenosyltransferase (MAT) (1) Mitochondrial Metabolism (4) MMP (2) MOFs (1) Molecular Glues (1) Monoamine Transporter (1) Neurokinin Receptor (2) NF-κB (1) Notch (1) Nucleoside Antimetabolite/Analog (1) OAT (1) Parasite (1) PARP (4) PD-1/PD-L1 (4) PERK (1) Prolyl Endopeptidase (PREP) (1) Prostaglandin Receptor (1) PSMA (13) Radionuclide-Drug Conjugates (RDCs) (37) Reactive Oxygen Species (ROS) (2) Reference Standards (3) Ser/Thr Protease (1) Sigma Receptor (1) Somatostatin Receptor (5) Transmembrane Glycoprotein (3) TROP2 (1) TrxR (1) TSPO (3) VEGFR (1) VISTA (1)
By Research Areas:	Cancer (156) Cardiovascular Disease (3) Endocrinology (1) Infection (3) Inflammation/Immunology (9) Metabolic Disease (3) Neurological Disease (6)
Click Chemistry:	Labeling and Fluorescence Imaging (1) DBCO (1) Azide (1) Tetrazine (1) Alkynes (1)
Oligonucleotides:	Fluorescent Lipids (1) Pegylated Lipids (1) Aptamers (1) Nucleoside Analogs (1) Suspending Agents (1) Uridine (1) Emulsifiers (1)

156

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Targets Recommended: Large Tumor Suppressor (LATS) TNF Receptor BRK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-128890

DOTA-NHS-ester 1 Publications Verification	ADC Linker	Cancer
DOTA-NHS-ester is a linker for affibody molecules and is applied in small animals PET, SPECT, and CT. DOTA-NHS-ester can be used to label radiotherapeutic agents or imaging probes for the detection of tumors .

HY-128643

FAPI-4 Maximum Cited Publications 31 Publications Verification	FAP	Cancer
FAPI-4 is a potent fibroblast activation protein (FAP) inhibitor for the targeting FAP. FAPI-4 can be used in cancer research. ⁶⁸Ga-FAPI-4 PET/CT is a promising new diagnostic method for imaging various kinds of cancer, with good tumor-to-background contrast ratios .

HY-137331

FAPI-46 2 Publications Verification	FAP	Cancer
FAPI-46 is a quinoline-based fibroblast activation protein (FAP)-targeted tracer. Use radioactivity FAPI-46 labeled with ⁶⁸Ga or ¹⁷⁷Lu can be used for tumor imaging in a variety of cancers and has higher tumor uptake rates and longer tumor accumulation .

HY-D1063

IR-780 Maximum Cited Publications 6 Publications Verification	Fluorescent Dye Apoptosis Reactive Oxygen Species (ROS)	Cancer
IR-780 is a near-infrared fluorescent probe for in vivo imaging of tumor cells. IR-780 is transported into tumor cells via OATPs and ABCB10, with uptake dependent on glycolytic activity and plasma membrane potential. IR-780 preferentially accumulates in tumor cell mitochondria, including those of drug-resistant cancer cells, without chemical conjugation. IR-780 generates reactive oxygen species (ROS), induces hyperthermia and apoptosis, inhibits tumor growth and recurrence, and modulates HSP70 expression upon ultrasound or 808 nm laser exposure. IR-780 acts as a sonosensitizer, photodynamic and photothermal agent, and drug delivery carrier, with low acute imaging-dose toxicity and rapid vital organ clearance. IR-780 can be used for the research of cancer, such as breast cancer, lung cancer, and non-small cell lung cancer (NSCLC) .

HY-W034551

DOTA-tri(t-butyl ester)	Radionuclide-Drug Conjugates (RDCs)	Others Cancer
DOTA-tri(t-butyl ester) belongs to the DOTA class of chelating agents. DOTA-tri(t-butyl ester) is a key raw material for synthesizing nanospherical magnetic resonance imaging (MRI) contrast agents, which are used in MR angiography and tumor angiogenesis imaging .

HY-W1126504

ETN029 MC339	Notch	Cancer
ETN029 (MC339) is a selective DLL3 ligand. ETN029 labeled with ²²⁵Ac has dose-dependent cytotoxicity in SCLC, NEPC and metastatic melanoma cells and increases the phosphorylation of H2AX expression. ETN029 labeled with 177Lu shows rapid uptake persistent tumor retention and favorable tumor-to-kidney ratio. ETN029 can be used for cancers like SCLC and NEPC imaging and research .

HY-139579

Pafolacianine 1 Publications Verification OTL 38	Fluorescent Dye	Cancer
Pafolacianine (OTL 38) is a fluorescent imaging agent made of near-infrared dye used in detecting tumor lesions during surgical procedures. Pafolacianine excites at 774 to 775 nm and emits at 794 to 796 nm .

HY-47979

FAP-IN-2 1 Publications Verification	FAP	Cancer
FAP-IN-2 is an isonitrile-containing fibroblast activation protein (FAP) inhibitor. FAP-IN-2 can be labeled with technetium-99m ( ^99mTc) for targeted tumor SPECT imaging .

HY-W053583

Tetraxetan 1 Publications Verification DOTA	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs)	Cancer
Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., ⁶⁸Ga, ¹¹¹In, ¹⁷⁷Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .

HY-145746

Sulfo-Cy5 azide	Fluorescent Dye PD-1/PD-L1	Inflammation/Immunology Cancer
Sulfo-Cy5 azide is a near-infrared fluorescent probe with favorable click chemistry reactivity. Sulfo-Cy5 azide enables fluorescence imaging, tissue and cellular visualization of PD-L1 in tumors, and site-specific modification of anti-PD-L1 antibodies. Sulfo-Cy5 azide has been employed for RNA labeling and imaging. Sulfo-Cy5 azide can be conjugated to targeting agents for fluorescence imaging in atherosclerosis and breast cancer models (Ex/Em = 645/670 nm) .

HY-D1464

CH1055 1 Publications Verification	Fluorescent Dye	Cancer
CH1055 is a near-infrared II (NIR-II) fluorescent dye that can be used as a fluorescent probe for in vivo imaging. CH1055 can be conjugated with antibodies or ligands for specific imaging (for example the tumor imaging) .

HY-D1872

800CW NHS ester	Fluorescent Dye	Others
800CW NHS ester is a near-infrared fluorescent dye active ester that can conjugate with amine-containing small molecules, antibodies, peptides, and other substances to form fluorescent conjugates. 800CW NHS ester exhibits high fluorescence quantum yield and low non-specific binding properties. 800CW NHS ester can be used in biomedical research such as microbial infection imaging, tumor imaging, and biochemical detection .

HY-P99289

Epratuzumab Antibody hLL 2; AMG-412	CD22	Inflammation/Immunology Cancer
Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases .

HY-P5128

DOTA-JR11 1 Publications Verification Satoreotide tetraxetan	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-JR11 is a somatostatin receptor 2 （SSTR2）antagonist. DOTA-JR11 can be labeled by 68Ga, used for paired imaging in neuroendocrine tumors (NETs) research . DOTA-JR11 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-20167A

H-Glu(OtBu)-OtBu hydrochloride	Neurokinin Receptor	Cancer
H-Glu(OtBu)-OtBu hydrochloride is a key intermediate that can be used to synthesize prostate-specific membrane antigen (PSMA) targeting probes. H-Glu(OtBu)-OtBu hydrochloride can reduce nonspecific background binding through negatively charged linkers, improve tumor/background contrast, and can be used in prostate cancer PET/SPECT imaging studies .

HY-139401

FAPI-34	FAP	Cancer
FAPI-34 is a SPECT imaging agent targeting FAP. FAPI-34 specifically binds to FAP, is highly internalized by FAP-expressing cells, accumulates in FAP-expressing tumor lesions, and shows low uptake in normal tissues except the kidneys. FAPI-34 is applicable for tumor-related research .

HY-D1719

Cypate 1 Publications Verification	Fluorescent Dye	Others
Cypate, a cyanine dye, is a near infrared (NIR) fluorescent probe for in vivo tumor imaging .

HY-149931

BMV109	Fluorescent Dye	Cancer
BMV109 is a quenched probe that becomes fluorescent when cleaved and covalently bound by active cathepsin proteases. BMV109 can be exploited for tumor imaging .

HY-122607

DPA-714	Mitochondrial Metabolism TSPO	Inflammation/Immunology Cancer
DPA-714 is a high affinity translocator protein (TSPO) ligand (K_i=7 nM), which is designed with a fluorine atom in its structure, allowing labelling with fluorine -18 and in vivo imaging using positron emission tomography. ^18FDPA-714 successfully evaluates for the specific imaging of inflammation in various models of neuroinflammation and in a brain tumor model .

HY-120115

PARPi-FL Olaparib-bodipy FL	PARP Fluorescent Dye	Cancer
PARPi-FL (Olaparib-bodipy FL) is a small-molecule fluorescent inhibitor of PARP1 that can specifically bind to PARP1. PARPi-FL can be used as a fluorescent imaging agent for tumor detection, diagnosis, and surgical guidance .

HY-P10131

3BP-3940	Radionuclide-Drug Conjugates (RDCs) FAP	Cancer
3BP-3940 is a highly potent and selective peptide inhibitor of FAP that targets cancer-associated fibroblasts (CAFs) in the tumor microenvironment. 3BP-3940 can be labeled with radionuclides (such as Ga-68) for precise tumor imaging or Lu-177 for the development of targeted anticancer technologies. 3BP-3940 accumulates in tumor lesions and can be used to diagnose and inhibit various solid cancers and CAFs-related diseases .

HY-D1719A

Cypate hydrochloride 1 Publications Verification	Fluorescent Dye	Cancer
Cypate is a near-infrared fluorescent dye that belongs to the family of photosensitizers. Cypate has high photostability and optical properties, and is often used in near-infrared optical imaging, as well as optical imaging, tumor marking, and drug delivery. In addition, Cypate is also used as a molecular probe and combined with targeting molecules (such as CBT or small interfering RNA) to achieve efficient detection and imaging of specific cells or tissues .

HY-161074

PNT6555	FAP	Cancer
PNT6555 is a fibroblast activation protein-α (FAP) inhibitor. PNT6555 has antitumor activity. PNT6555 can be used for imaging of FAP-positive tumors .

HY-P10292

NOTA-Pep-1L	Radionuclide-Drug Conjugates (RDCs) Interleukin Related	Cancer
NOTA-Pep-1L specifically targets the IL13RA2 receptor for tumor imaging . NOTA-Pep-1L can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P1043

NGR peptide 1 Publications Verification	Aminopeptidase	Cancer
NGR peptide containing the Asn-Gly-Arg (NGR) motif. NGR peptide binds to APN/CD13. NGR peptide is directly conjugated to imaging agents that can be used for tumor imaging .

HY-P6083

RTSPSSR	Biochemical Assay Reagents	Others Cancer
RTSPSSR is synthesized peptide, which binds specifically to claudin-1 and visulizes the CRC tumor in mice, through near-infrared fluorescence imaging .

HY-136201

Sodium Glucoheptonate	Biochemical Assay Reagents	Cancer
Sodium Glucoheptonate is used as a kit for radio-labeling with Tc-99m. Tc-99m glucoheptonate is kidney- and brain-imaging agent, and can be used in brain-tumor detection .

HY-175613

DOTA-ALB-02	FAP	Cancer
DOTA-ALB-02 is an albumin-bound FAP inhibitor (FAPI) ligand. DOTA-ALB-02 labeled with ¹⁷⁷Lu has a high FAP-binding affinity and enhanced tumor uptake and retention with a significant tumor/nontarget ratio. DOTA-ALB-02 can be used for PET/CT and SPECT/CT imaging of cancers, especially late-stage cancers .

HY-128890B

DOTA-NHS-ester TFA 1 Publications Verification	ADC Linker Biochemical Assay Reagents	Cancer
DOTA-NHS-ester (TFA) is used as a linker for affibody molecules, and it can be employed in small animal positron emission tomography (PET), single photon emission computed tomography (SPECT), and CT scanning. DOTA-NHS-ester can be used to label radiotracers or imaging probes for tumor detection .

HY-P10792

HER2-targeted peptide H6F	EGFR	Cancer
HER2-targeted peptide H6F is a HER2 targeting peptide that binds to HER2 to target breast cancer cells, with the amino acid sequence YLFFVFER. The HER2-targeted peptide H6F can be conjugated with the bifunctional chelating agent hydrazinonicotinamide (HYNIC) for radiolabeling with 99mTc. Single-photon emission computed tomography (SPECT) imaging shows that the labeled HER2-targeted peptide H6F specifically accumulates in HER2-positive MDA-MBA-453 tumor-bearing mice models. The HER2-targeted peptide H6F can be used for tumor molecular imaging studies .

HY-P11339

c-RGD-SH	Integrin	Cancer
c-RGD-SH is a ligand for integrin αvβ3 (Integrin αvβ3). Conjugation of c-RGD-SH with core-crosslinked polymeric micelles (CCPM) enables the synthesis of a bimodal nanoprobe, which can be labeled with Cy7 and 111In for SPECT and NIRF imaging of tumors .

HY-158072

DOTAM-NHS-ester	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTAM-NHS-ester is a bifunctional chelator and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTAM-NHS-ester combines the efficient metal chelating ability of DOTAM macrocyclic ligands with the bioconjugation function of NHS ester active groups, and can be widely used in the biomedical field for metal labeling, molecular imaging and drug delivery development .

HY-D1464A

CH1055 triethylamine 1 Publications Verification	Fluorescent Dye	Cancer
CH1055 triethylamine is a near-infrared II (NIR-II) fluorescent dye that can be used as a fluorescent probe for in vivo imaging. CH1055 triethylamine can be conjugated with antibodies or ligands for specific imaging (for example the tumor imaging) .

HY-159045

F-SAHA p-Fluoro-SAHA	HDAC	Cancer
F-SAHA is a HDAC inhibitor (HDACi) and its ¹⁸F labeled derivative can be used in tumor imaging research .

HY-D1450

IR-1048 S01448	Fluorescent Dye	Cancer
IR-1048 is a nitroreductase (NTR)-responsive near-infrared fluorescence (NIR)/photoacoustic (PA) imaging probe and photothermal agent. IR-1048 is coupled with a nitroimidazole group to form IR-1048-MZ. IR-1048-MZ is catalytically reduced by NTR in a hypoxic environment, restoring strong near-infrared absorption and fluorescence emission (NIR II window), while activating the photothermal effect. IR-1048 relies on NTR-mediated electron transfer to relieve intramolecular fluorescence quenching, achieving specific imaging and photothermal ablation of tumor hypoxic areas. IR-1048 is mainly used for high-contrast NIR II/photoacoustic imaging and photothermal therapy research and tumor diagnosis of the tumor hypoxic microenvironment .

HY-177459

DOTA-2P(FAPI)2	FAP	Cancer
DOTA-2P(FAPI)2 is a dimeric FAP (fibroblast activation protein) that can be used as a PET imaging agent and a tracer for tumor therapy .

HY-139579A

Pafolacianine tetrasodium OTL 38 tetrasodium	Fluorescent Dye	Cancer
Pafolacianine tetrasodium (OTL 38 tetrasodium) is a fluorescent imaging agent made of near-infrared dye used in detecting tumor lesions during surgical procedures. Pafolacianine tetrasodium excites at 774 to 775 nm and emits at 794 to 796 nm .

HY-123733A

MIP-1095 TFA RPS-001 TFA	PSMA	Cancer
MIP-1095 (RPS-001) TFA is a potent inhibitor of PSMA with good biodistribution and efficient targeting of tumor lesions. In applications, MIP-1095 TFA will be isotopically labeled ( ¹³¹I labeled) as an imaging probe to indicate tumor progression. And ¹³¹I-MIP-1095 showed higher renal uptake in mice .

HY-P2022

Pentetreotide	Radionuclide-Drug Conjugates (RDCs)	Cancer
Pentetreotide is a diethylenetriaminopentaacetic (DTPA) conjugate of Octreotide (HY-P0036). Pentetreotide is a somatostatin analog that, when labeled with ¹¹¹In, can be used for nuclear medicine imaging. Somatostatin receptor scintigraphy with Pentetreotide is effective in visualizing neuroendocrine tumors, and its metastasis .

HY-175744

PSMA-MAL-5	PSMA	Cancer
PSMA-MAL-5 is a PSMA ligand. PSMA-MAL-5 covalently binds to Cys466 of PSMA. PSMA-MAL-5 labeled with ¹⁷⁷Lu and ²²⁵Ac has high radiostability and tumor uptake. PSMA-MAL-5 also effectively inhibits tumor growth. PSMA-MAL-5 can be used for SPECT/CT imaging and radionuclide therapy of prostate cancer .

HY-P1043A

NGR peptide Trifluoroacetate 1 Publications Verification	Aminopeptidase	Cancer
NGR peptide Trifluoroacetatecontaining the Asn-Gly-Arg (NGR) motif. NGR peptide Trifluoroacetate binds to APN/CD13. NGR peptide Trifluoroacetate is directly conjugated to imaging agents that can be used for tumor imaging .

HY-D2281

FAP Ligand 2	FAP	Cancer
FAP Ligand 2, a FAPI-46 derivative, is a specific fibroblast activation protein (FAP)-targeted tracer. FAP Ligand 2 exhibits good tumor uptake and acts as a promising molecular tracer for FAP tumor imaging .

HY-174421

FAPI-JNU	FAP	Cancer
FAPI-JNU is a molecule targeting fibroblast activation protein (FAP). FAPI-JNU specifically binds to FAP highly expressed in the tumor microenvironment, and uses radionuclides [ ⁶⁸Ga]Ga or [ ¹⁷⁷Lu]Lu to achieve tumor imaging diagnosis. [177Lu]Lu−FAPI−JNU can effectively target and inhibit tumor growth in tumor-bearing mice. FAPI-JNU is promising for research of FAP-positive tumors (such as various solid tumors) .

HY-47979A

FAP-IN-2 TFA 1 Publications Verification	FAP	Cancer
FAP-IN-2 TFA is an isonitrile-containing fibroblast activation protein (FAP) inhibitor. FAP-IN-2 TFA can be labeled with technetium-99m ( ^99mTc) for targeted tumor SPECT imaging .

HY-P11026

DOTA-TMVP1446 DOTA-PEG4-TMVP1446	VEGFR	Cancer
DOTA-TMVP1446 is a VEGFR-3 targeting peptide. DOTA-TMVP1446 labeled with ⁶⁸Ga accurately detectes the status of lymph node metastasis, even in micrometastatic tumors, in the B16-F10 tumor mice model. DOTA-TMVP1446 can be used as a radiotracer for cancer-metastatic sentinel lymph nodes (m-SLN) imaging .

HY-175685

FAP-IN-7	FAP	Cancer
FAP-IN-7 (Compound 5b) is a FAPtumor retention with high selectivity and favorable pharmacokinetics. FAP-IN-7 can be used as a radiotracer for PET imaging and radionuclide therapy of cancers research .

HY-P11339A

c-RGD-SH TFA	Integrin	Cancer
c-RGD-SH TFA is an Integrin αvβ3 ligand. c-RGD-SH TFA conjugated with core-crosslinked polymeric micelles (CCPM) can be used for synthesis a dual modality nanoparticle probe, and this probe labeled with both Cy7 and ¹¹¹In can be used for SPECT and NIRF imaging of tumor .

HY-129040

m-Iodobenzylguanidine 1 Publications Verification MIBG; Iobenguane	Monoamine Transporter	Neurological Disease Endocrinology Cancer
m-Iodobenzylguanidine (Iobenguane) is a ligand with high affinity against norepinephrine transporter (NET). m-Iodobenzylguanidine is used as an imaging agent in the diagnostic imaging and radionuclide studies of neuroendocrine tumors, such as neuroblastoma, pheochromocytoma and carcinoid tumor .

HY-149298

PSMA-IN-2	PSMA	Cancer
PSMA-IN-2 is an inhibitor of PSMA with a K_i value of 1.07 nM. PSMA-IN-2 displays favorable in vivo NIR imaging (λ_EM = 1088 nm, λ_ex = 808 nm), and can be used for NIRII image-guided tumor resection surgery in PSMA-positive tumor-bearing mice .

HY-180450

Caloxetate trisodium	Biochemical Assay Reagents	Cancer
Gadoxetate disodium is a liver-specific magnetic resonance imaging (MRI) contrast agent, can be used for detecting and identifying liver tumors .

Cat. No.	Product Name	Type

HY-D1063

IR-780

Maximum Cited Publications

6 Publications Verification

Fluorescent Dyes

IR-780 is a near-infrared fluorescent probe for in vivo imaging of tumor cells. IR-780 is transported into tumor cells via OATPs and ABCB10, with uptake dependent on glycolytic activity and plasma membrane potential. IR-780 preferentially accumulates in tumor cell mitochondria, including those of drug-resistant cancer cells, without chemical conjugation. IR-780 generates reactive oxygen species (ROS), induces hyperthermia and apoptosis, inhibits tumor growth and recurrence, and modulates HSP70 expression upon ultrasound or 808 nm laser exposure. IR-780 acts as a sonosensitizer, photodynamic and photothermal agent, and drug delivery carrier, with low acute imaging-dose toxicity and rapid vital organ clearance. IR-780 can be used for the research of cancer, such as breast cancer, lung cancer, and non-small cell lung cancer (NSCLC) .

HY-139579

Pafolacianine 1 Publications Verification OTL 38	Fluorescent Dyes
Pafolacianine (OTL 38) is a fluorescent imaging agent made of near-infrared dye used in detecting tumor lesions during surgical procedures. Pafolacianine excites at 774 to 775 nm and emits at 794 to 796 nm .

HY-145746

Sulfo-Cy5 azide

Fluorescent Dyes

Sulfo-Cy5 azide is a near-infrared fluorescent probe with favorable click chemistry reactivity. Sulfo-Cy5 azide enables fluorescence imaging, tissue and cellular visualization of PD-L1 in tumors, and site-specific modification of anti-PD-L1 antibodies. Sulfo-Cy5 azide has been employed for RNA labeling and imaging. Sulfo-Cy5 azide can be conjugated to targeting agents for fluorescence imaging in atherosclerosis and breast cancer models (Ex/Em = 645/670 nm) .

HY-D1464

CH1055 1 Publications Verification	Fluorescent Dyes
CH1055 is a near-infrared II (NIR-II) fluorescent dye that can be used as a fluorescent probe for in vivo imaging. CH1055 can be conjugated with antibodies or ligands for specific imaging (for example the tumor imaging) .

HY-D1872

800CW NHS ester

Fluorescent Dyes

800CW NHS ester is a near-infrared fluorescent dye active ester that can conjugate with amine-containing small molecules, antibodies, peptides, and other substances to form fluorescent conjugates. 800CW NHS ester exhibits high fluorescence quantum yield and low non-specific binding properties. 800CW NHS ester can be used in biomedical research such as microbial infection imaging, tumor imaging, and biochemical detection .

HY-D0053

6-ROX 6-Carboxy-X-rhodamine	Fluorescent Dyes
6-ROX is a selective fluorescent probe and potential inhibitor of COX-2. 6-ROX binds to the active site of COX-2 and inhibits its conversion of arachidonic acid into prostaglandins. 6-ROX is often used in the field of optical imaging related to tumors and inflammation, and helps detect diseased tissues with high expression of COX-2 .

HY-D1716

S0456	Fluorescent Dyes
S0456 is a raw material that plays a crucial role in the construction of the folate receptor-targeted near-infrared dye OTL 38 (HY-139579). S0456 is connected to the modified folic acid to form OTL 38, endowing OTL 38 with good optical properties, high affinity, and specificity. S0456 can be used in the research of tumor optical imaging agents .

HY-D2062

ATTO 740 NHS ester

Fluorescent Dyes

ATTO 740 NHS ester is a near-infrared fluorescent dye and a multimodal fluorescence/photoacoustic contrast agent with excellent near-infrared emission properties and extremely high photostability. The photoacoustic signal of ATTO 740 NHS ester shows no significant decrease after continuous irradiation with a 750 nm laser for 30 min, making it suitable for in vivo fluorescence imaging and photoacoustic contrast imaging. When conjugated with the cystine knot peptide R01, ATTO 740 NHS ester enables precise detection of integrin αvβ6-positive cells and tumors in nude mouse xenograft models .

HY-D1464A

CH1055 triethylamine 1 Publications Verification	Fluorescent Dyes
CH1055 triethylamine is a near-infrared II (NIR-II) fluorescent dye that can be used as a fluorescent probe for in vivo imaging. CH1055 triethylamine can be conjugated with antibodies or ligands for specific imaging (for example the tumor imaging) .

HY-D2281

FAP Ligand 2	Fluorescent Dyes
FAP Ligand 2, a FAPI-46 derivative, is a specific fibroblast activation protein (FAP)-targeted tracer. FAP Ligand 2 exhibits good tumor uptake and acts as a promising molecular tracer for FAP tumor imaging .

HY-151704

ICG-alkyne

Fluorescent Dyes

ICG-alkyne is a short-wave infrared (SWIR)-emitting cyanine fluorescent probe based on alkyne-derivatized indocyanine green. ICG-alkyne can undergo click chemistry reaction to conjugate with antibody molecules via binding to the azide groups introduced into antibodies. ICG-alkyne enables SWIR fluorescent molecular imaging of breast tumors in living mice. ICG-alkyne can be used in breast cancer-related research .

HY-D2285

MOR-CES2	Fluorescent Dyes
MOR-CES2 is a near-infrared fluorescent probe (E_x= 630 nm, E_m=735 nm) capable of identifying cancer cells and tissues, as well as exhibiting a sensitive response to inflammation. MOR-CES2 holds potential as an efficient imaging tool in assisting surgical resection of CES2-related tumors .

HY-162051

CYP1B1-IN-6	Fluorescent Dyes
CYP1B1-IN-6 (compound 19) is a fluorescence molecular probes which inhibits CYP1B1 activity. CYP1B1-IN-6 can identify tumor sites in fluorescence imaging and photoacoustic imaging modes .

HY-D2334

AlF-NOTA-c-d-VAP	Fluorescent Dyes
AlF-NOTA-c-d-VAP is a peptide positron emission tomography (PET) probe that used for targeted tumor imaging of GRP78. AlF-NOTA-c-d-VAP demonstrates high stability in vitro and in vivo .

HY-D3353

PSMA-SulfoCy7

Fluorescent Dyes

PSMA-SulfoCy7 is a high-affinity imaging agent targeting PSMA/GCPII (with a K_i of 18.1 nM for human PSMA). PSMA-SulfoCy7 regulates PSMA-dependent NAAG hydrolysis. PSMA-SulfoCy7 exhibits excellent in vivo imaging capability, enabling clear visualization of PSMA-expressing tumors in xenograft models, with no obvious toxicity even at a dose of 87.9 mg/kg. PSMA-SulfoCy7 is widely used in prostate cancer-related studies .

HY-D3187

HMRef-αMan

Fluorescent Dyes

HMRef-αMan is a substrate-based green fluorescent probe (Ex/Em=465 nm/515 nm) targeting MAN2C1 (α-mannosidase). HMRef-αMan can be specifically cleaved by MAN2C1 to generate a highly fluorescent product, which thus gets activated to produce green fluorescence in malignant breast tissues, benign lesions and living cancer cells. The signal intensity of HMRef-αMan is directly correlated with MAN2C1 activity, and it can effectively detect tiny breast cancer lesions with a diameter of less than 1 mm. When used in combination with the red-emitting γ-glutamyl transpeptidase (GGT) probe gGlu-2OMe SiR600 (HY-D3188), HMRef-αMan enables precise optical differentiation of breast tissue types via a dual-color imaging strategy. HMRef-αMan has been widely used in the research of breast diseases such as breast cancer, fibroadenoma, phyllodes tumor and various types of papilloma .

Cat. No.	Product Name	Type

HY-W053583

Tetraxetan

1 Publications Verification

DOTA

Biochemical Assay Reagents

Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., ⁶⁸Ga, ¹¹¹In, ¹⁷⁷Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .

HY-W440911

DSPE-PEG2000-Cy5

Biochemical Assay Reagents

DSPE-PEG2000-Cy5 is a Cy5 (HY-D0821) fluorophore-labeled conjugate of distearoylphosphatidylethanolamine and polyethylene glycol, as well as a liposome component. The Cy5 fluorophore is commonly used for labeling proteins and nucleic acids in imaging, flow cytometry and genomic applications. DSPE-PEG2000-Cy5 supports cell membrane modification, in vivo tumor targeting research and long-term in vivo circulation of its liposomal formulations (Ex/Em=633/670 nm) .

HY-W250149

Chlorophosphonazo III

Biochemical Assay Reagents

Chlorophosphonazo III is a cell membrane-permeable contrast agent and spectrophotometric reagent. Chlorophosphonazo III forms stable 1:1 complexes with intracellular calcium, magnesium, uranium, titanium, zirconium, thorium, scandium, equivalent actinides and protactinium. Chlorophosphonazo III generates photoacoustic signals correlated with Ca ²⁺ concentrations, which is applicable for imaging 3D tumor cell cultures and tumor spheroids. Chlorophosphonazo III exhibits no cytotoxicity, can be used for spectrophotometric detection of target ions, and the absorbance of its complexes remains stable for up to one week within the pH range of 2.2 to 7.0 .

HY-100133A

DOTA-ADIBO TFA	Biochemical Assay Reagents
DOTA-ADIBO TFA is a DOTA-derived bifunctional chelator (BFC) that allows drug conjugation via an uncatalyzed, copper-free cycloaddition reaction. DOTA-ADIBO TFA enables the construction of fusion chelator systems that can be further used to synthesize radiotracers after Cu[64] modification. Positron emission tomography imaging of tumors expressing integrin αvβ6 .

HY-158067

Deferoxamine-DBCO

DFO-DBCO

Biochemical Assay Reagents

Deferoxamine-DBCO is a bifunctional chelating agent. Deferoxamine-DBCO efficiently chelates with radioactive metals (such as ⁸⁹Zr) through the DFO structure to achieve radiolabeling. Deferoxamine-DBCO undergoes a metal-free Huisgen cycloaddition reaction with azide-containing biomolecules (such as siRNA, monoclonal antibodies) under bioorthogonal conditions through the DBCO structure to achieve targeted coupling. Deferoxamine-DBCO has efficient metal chelating ability and specific bioorthogonal reaction activity. Deferoxamine-DBCO can be used for targeted radioactive imaging studies of tumors .

HY-158072

DOTAM-NHS-ester	Biochemical Assay Reagents
DOTAM-NHS-ester is a bifunctional chelator and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTAM-NHS-ester combines the efficient metal chelating ability of DOTAM macrocyclic ligands with the bioconjugation function of NHS ester active groups, and can be widely used in the biomedical field for metal labeling, molecular imaging and drug delivery development .

HY-W053583R

Tetraxetan (Standard)

DOTA (Standard)

Biochemical Assay Reagents

Tetraxetan (Standard) is the analytical standard of Tetraxetan (HY-W053583). This product is intended for research and analytical applications. Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., ⁶⁸Ga, ¹¹¹In, ¹⁷⁷Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .

HY-173384

DSPE-DOTA sodium 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N- tetraazacyclododecane-N-tetraacetic acid, sodium salt	Biochemical Assay Reagents
DSPE-DOTA sodium (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N- tetraazacyclododecane-N-tetraacetic acid, sodium salt) is a chelating lipid used as a key contrast agent in magnetic resonance imaging (MRI). DSPE-DOTA sodium can be used for imaging detection of tumors, neurological and inflammatory diseases .

Cat. No.	Product Name	Target	Research Area

HY-P10761

DPI-4452	Radionuclide-Drug Conjugates (RDCs) Carbonic Anhydrase	Cancer
DPI-4452 is a CAIX-targeting cyclic peptide with a DOTA cage, and can be chelated with radionuclide for CAIX-expressing tumor PET-CT imaging and study. DPI-4452 specifically and selectively binds CAIX without interaction with an in vitro off-target receptor panel of 55 targets (IC₅₀ for recombinant hCAIX: 130 nM). Radiolabeled DPI-4452 inhibits tumor growth in HT-29 and SK-RC-52 xenograft mouse models . DPI-4452 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5128

DOTA-JR11 1 Publications Verification Satoreotide tetraxetan	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-JR11 is a somatostatin receptor 2 （SSTR2）antagonist. DOTA-JR11 can be labeled by 68Ga, used for paired imaging in neuroendocrine tumors (NETs) research . DOTA-JR11 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-20167A

H-Glu(OtBu)-OtBu hydrochloride	Neurokinin Receptor	Cancer
H-Glu(OtBu)-OtBu hydrochloride is a key intermediate that can be used to synthesize prostate-specific membrane antigen (PSMA) targeting probes. H-Glu(OtBu)-OtBu hydrochloride can reduce nonspecific background binding through negatively charged linkers, improve tumor/background contrast, and can be used in prostate cancer PET/SPECT imaging studies .

HY-P4116

pH-Low Insertion Peptide pHLIP	Peptides	Metabolic Disease Cancer
pH-Low Insertion Peptide (pHLIP) is a short, pH-responsive peptide capable of inserting across a cell membrane to form a transmembrane helix at acidic pH. pH-Low Insertion Peptide targets the acidic tumor microenvironment for tumors at early and metastatic stages with high specificity, used as a specific ligand. pH-Low Insertion Peptide successfully modify polylysine polymers to have the pH-responsive capability. pH-Low Insertion Peptide-based targeting of cancer presents an opportunity to monitor metabolic changes, and to selectively deliver imaging and therapeutic agents to tumors .

HY-D2363

DOTA.SA.FAPi TFA	Radionuclide-Drug Conjugates (RDCs) FAP Prolyl Endopeptidase (PREP)	Cancer
DOTA.SA.FAPi TFA is a selective FAP inhibitor with an IC₅₀ value of 0.9 nM against FAP. DOTA.SA.FAPi TFA forms stable complexes with ⁶⁸Ga and serves as a PET radiotracer for preclinical imaging of FAP-expressing tumors. DOTA.SA.FAPi TFA can be used in the research of colorectal adenocarcinoma and various other cancers .

HY-P5362

NODAGA-LM3	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Neurological Disease Cancer
NODAGA-LM3 is a ligand that can cross the blood-brain barrier and targets somatostatin receptor SSTR2 with high affinity (IC₅₀ = 1.3 nM). NODAGA-LM3 does not trigger the internalization of SSTR2 and can inhibit agonist-induced internalization processes. NODAGA-LM3 shows low uptake in normal tissues such as the liver and spleen, but high uptake in the lungs and blood pool. ⁶⁸Ga-labeled NODAGA-LM3 can serve as a PET imaging agent for well-differentiated neuroendocrine tumors, and is applied in studies related to small cell lung cancer and well-differentiated neuroendocrine tumors .

HY-P11287A

DOTA-Pep-1L TFA	Interleukin Related Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-Pep-1L TFA is a polypeptide formed by the conjugation of DOTA and Pep-1L. DOTA-Pep-1L TFA specifically binds to IL13RA2 and can be used for the synthesis of targeted polypeptides. DOTA-Pep-1L TFA yields the isotopically labeled product [ ²²⁵Ac]DOTA-Pep-1L, which exerts α-radiation killing effects on orthotopic glioma cells and extends the median survival time of mice bearing orthotopic glioma models after stereotactic injection. DOTA-Pep-1L TFA can be used for PET imaging, tumor targeting and glioma research .

HY-P10131

3BP-3940	Radionuclide-Drug Conjugates (RDCs) FAP	Cancer
3BP-3940 is a highly potent and selective peptide inhibitor of FAP that targets cancer-associated fibroblasts (CAFs) in the tumor microenvironment. 3BP-3940 can be labeled with radionuclides (such as Ga-68) for precise tumor imaging or Lu-177 for the development of targeted anticancer technologies. 3BP-3940 accumulates in tumor lesions and can be used to diagnose and inhibit various solid cancers and CAFs-related diseases .

HY-P5018

NOTA-AE105	Radionuclide-Drug Conjugates (RDCs) Ser/Thr Protease	Cancer
NOTA-AE105 is a PET ligand for the urokinase-type plasminogen activator receptor (uPAR). NOTA-AE105 can be radiolabeled with ⁶⁴Cu and ⁶⁸Ga. Images of 68Ga-NOTA-AE105 and 64Cu-NOTA-AE105 demonstrate high contrast and clear tumor delineation. NOTA-AE105 can be used in the synthesis of radionuclide-conjugated compounds (RDCs) .

HY-P10292

NOTA-Pep-1L	Radionuclide-Drug Conjugates (RDCs) Interleukin Related	Cancer
NOTA-Pep-1L specifically targets the IL13RA2 receptor for tumor imaging . NOTA-Pep-1L can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5290

HYNIC-PSMA	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
HYNIC-PSMA is a ligand for molecular imaging of tumors. Hynic-psma consists of two components: HYNIC (6-hydrazinonicotinamide) and PSMA (Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules, such as ¹⁸⁸Re-HYNIC-PSMA. PSMA is a membrane antigen that is specifically expressed on the surface of prostate cancer cells. HYNIC-PSMA can be used in prostate cancer research . HYNIC-PSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P1043

NGR peptide 1 Publications Verification	Aminopeptidase	Cancer
NGR peptide containing the Asn-Gly-Arg (NGR) motif. NGR peptide binds to APN/CD13. NGR peptide is directly conjugated to imaging agents that can be used for tumor imaging .

HY-P6083

RTSPSSR	Biochemical Assay Reagents	Others Cancer
RTSPSSR is synthesized peptide, which binds specifically to claudin-1 and visulizes the CRC tumor in mice, through near-infrared fluorescence imaging .

HY-P10792

HER2-targeted peptide H6F	EGFR	Cancer
HER2-targeted peptide H6F is a HER2 targeting peptide that binds to HER2 to target breast cancer cells, with the amino acid sequence YLFFVFER. The HER2-targeted peptide H6F can be conjugated with the bifunctional chelating agent hydrazinonicotinamide (HYNIC) for radiolabeling with 99mTc. Single-photon emission computed tomography (SPECT) imaging shows that the labeled HER2-targeted peptide H6F specifically accumulates in HER2-positive MDA-MBA-453 tumor-bearing mice models. The HER2-targeted peptide H6F can be used for tumor molecular imaging studies .

HY-P11339

c-RGD-SH	Integrin	Cancer
c-RGD-SH is a ligand for integrin αvβ3 (Integrin αvβ3). Conjugation of c-RGD-SH with core-crosslinked polymeric micelles (CCPM) enables the synthesis of a bimodal nanoprobe, which can be labeled with Cy7 and 111In for SPECT and NIRF imaging of tumors .

HY-P10934

LXY3 LXY2	Integrin	Cancer
LXY3 (LXY2) is a VLA-3-blocking peptide that inhibits the interaction between integrin α3β1 (VLA-3) on neutrophil surfaces and laminin in the basement membrane, thereby preventing neutrophil migration across the tumor vascular basement membrane barrier. LXY3 is used to block neutrophil-mediated nanoparticle release from perivascular pools into the tumor interstitium. LXY3 is commonly employed for targeted imaging of breast cancer .

HY-P2022

Pentetreotide	Radionuclide-Drug Conjugates (RDCs)	Cancer
Pentetreotide is a diethylenetriaminopentaacetic (DTPA) conjugate of Octreotide (HY-P0036). Pentetreotide is a somatostatin analog that, when labeled with ¹¹¹In, can be used for nuclear medicine imaging. Somatostatin receptor scintigraphy with Pentetreotide is effective in visualizing neuroendocrine tumors, and its metastasis .

HY-P4116A

pH-Low Insertion Peptide TFA pHLIP TFA	Peptides	Metabolic Disease Cancer
pH-Low Insertion Peptide TFA (pHLIP TFA) is a short, pH-responsive peptide capable of inserting across a cell membrane to form a transmembrane helix at acidic pH. pH-Low Insertion Peptide TFA targets the acidic tumor microenvironment for tumors at early and metastatic stages with high specificity, used as a specific ligand. pH-Low Insertion Peptide TFA successfully modifys polylysine polymers to have the pH-responsive capability. pH-Low Insertion Peptide TFA -based targeting of cancer presents an opportunity to monitor metabolic changes and to selectively deliver imaging and therapeutic agents to tumors .

HY-P5292A

HYNIC-iPSMA TFA	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
HYNIC-iPSMA TFA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA TFA has excellent specificity and sensitivity . HYNIC-iPSMA TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P11050A

SP94	Apoptosis	Cancer
SP94 is a peptide ligand with high specificity for hepatocellular carcinoma cells. SP94 selectively binds to multiple hepatocellular carcinoma cell lines in vitro. SP94 inhibits tumor growth in a mouse model of hepatocellular carcinoma by promoting apoptosis and reducing angiogenesis. SP94 can be used as a specific probe for hepatocellular carcinoma imaging. SP94 is useful for hepatocellular carcinoma research .

HY-P11287

DOTA-Pep-1L	Interleukin Related Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-Pep-1L is a polypeptide formed by the conjugation of DOTA and Pep-1L. DOTA-Pep-1L specifically binds to IL13RA2 and can be used for the synthesis of targeted polypeptides. DOTA-Pep-1L yields the isotopically labeled product [ ²²⁵Ac]DOTA-Pep-1L, which exerts α-radiation killing effects on orthotopic glioma cells and extends the median survival time of mice bearing orthotopic glioma models after stereotactic injection. DOTA-Pep-1L can be used for PET imaging, tumor targeting and glioma research .

HY-P2496

Endothelin 1 (swine, human), Alexa Fluor 488-labeled	Endothelin Receptor Fluorescent Dye NF-κB COX Prostaglandin Receptor Apoptosis TNF Receptor Interleukin Related MMP	Cardiovascular Disease Inflammation/Immunology Cancer
Endothelin 1 (swine, human), Alexa Fluor 488-labeled is an Endothelin-1 conjugated with Alexa Fluor 488 (HY-D1304). Endothelin-1 is an endogenous vasoconstrictor and agonist of ETA/ETB receptor. Endothelin 1 (swine, human) exerts effects including promoting mitosis, angiogenesis, tumor invasion and metastasis, and inhibiting apoptosis. Endothelin 1 (swine, human) induces inflammation and oxidative stress by activating the NF-κB pathway. Endothelin 1 (swine, human), Alexa Fluor 488-labeled is specifically designed for fluorescence imaging, flow cytometry or receptor localization studies, and can be used in research related to sepsis, atherosclerosis, systemic inflammatory response syndrome, cancer and congestive heart failure .

HY-P1043A

NGR peptide Trifluoroacetate 1 Publications Verification	Aminopeptidase	Cancer
NGR peptide Trifluoroacetatecontaining the Asn-Gly-Arg (NGR) motif. NGR peptide Trifluoroacetate binds to APN/CD13. NGR peptide Trifluoroacetate is directly conjugated to imaging agents that can be used for tumor imaging .

HY-P11026

DOTA-TMVP1446 DOTA-PEG4-TMVP1446	VEGFR	Cancer
DOTA-TMVP1446 is a VEGFR-3 targeting peptide. DOTA-TMVP1446 labeled with ⁶⁸Ga accurately detectes the status of lymph node metastasis, even in micrometastatic tumors, in the B16-F10 tumor mice model. DOTA-TMVP1446 can be used as a radiotracer for cancer-metastatic sentinel lymph nodes (m-SLN) imaging .

HY-P11339A

c-RGD-SH TFA	Integrin	Cancer
c-RGD-SH TFA is an Integrin αvβ3 ligand. c-RGD-SH TFA conjugated with core-crosslinked polymeric micelles (CCPM) can be used for synthesis a dual modality nanoparticle probe, and this probe labeled with both Cy7 and ¹¹¹In can be used for SPECT and NIRF imaging of tumor .

HY-P5292

HYNIC-iPSMA	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
HYNIC-iPSMA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA has excellent specificity and sensitivity . HYNIC-iPSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-114133

Depreotide	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
Depreotide is a nove tumor tarcer, can be complexed with technetium-99m ( ^99mTc-depreotide) for optimal imaging properties. ^99mTc-depreotide somatostain receptor imaging has been playing an important role in medical diagnosis research . Depreotide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10232

Hynic-toc HYNIC-Tyr3-octreotide	Radionuclide-Drug Conjugates (RDCs)	Cancer
Hynic-toc (HYNIC-Tyr3-octreotide), a octreotide derivative, can be conjugated with radioactive element for tumor imaging . Hynic-toc can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5520

GB-6	Bombesin Receptor Radionuclide-Drug Conjugates (RDCs)	Cancer
GB-6 is a short linear peptide that targets the gastrin releasing peptide receptor (GRPR). GRPR is overexpressed in pancreatic cancer. Based on the tumor selectivity and tumor-specific accumulation properties of GB-6, GB-6 labeled with near infrared (NIR) fluorescent dyes or radionuclide netium-99m (99mTc) can be used as a high-contrast imaging probe. GB-6 has excellent in vivo stability, with tumor to pancreatic and intestinal fluorescence signal ratios of 5.2 and 6.3, respectively, in SW199 0 subcutaneous xenograft models. GB-6 can rapidly target tumors and accurately delineate tumor boundaries, which has broad application prospects .

HY-P10743

BQ7876	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
BQ7876 is a probe targeting prostate-specific membrane antigen (PSMA) that contains a DOTA chelator. BQ7876, after being radiolabeled with radionuclide (177Lu), functions in both radionuclide imaging and tumor cell destruction by specifically binding to PSMA. BQ7876 shows potential for research in the field of metastatic castration-resistant prostate cancer (mCRPC) . BQ7876 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5362A

NODAGA-LM3 TFA	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
NODAGA-LM3 TFA is a ligand that can cross the blood-brain barrier and targets somatostatin receptor SSTR2 with high affinity (IC₅₀ = 1.3 nM). NODAGA-LM3 TFA does not trigger the internalization of SSTR2 and can inhibit agonist-induced internalization processes. NODAGA-LM3 TFA shows low uptake in normal tissues such as the liver and spleen, but high uptake in the lungs and blood pool. ⁶⁸Ga-labeled NODAGA-LM3 TFA can serve as a PET imaging agent for well-differentiated neuroendocrine tumors, and is applied in studies related to small cell lung cancer and well-differentiated neuroendocrine tumors .

HY-P11253

DOTA-Bn-CA-170	VISTA	Inflammation/Immunology
DOTA-Bn-CA-170 is a molecular probe targeting the VISTA protein, with a K_d value of 0.124 nM. DOTA-Bn-CA-170 is formed by covalently linking the p-SCN-Bn-DOTA ligand with CA-170 (HY-101093). DOTA-Bn-CA-170 labeled with [ ⁶⁸Ga]Ga successfully achieves specific and high-contrast PET imaging of VISTA expression in various tumor-bearing mouse models. DOTA-Bn-CA-170 can be used for the study of VISTA-targeted immunotherapy .

HY-P10744

BQ7859	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
BQ7859 is a probe targeting PSMA that contains a NOTA chelator and demonstrates excellent imaging performance. BQ7859 can be labeled with various radionuclides, such as 68Ga, 18F, 55Co, and 111In. In a mouse prostate cancer xenograft model, BQ7859 (labeled with 111In) efficiently accumulates in tumor regions in a PSMA-dependent manner and provides high-contrast tumor imaging. BQ7859 shows potential for research in prostate cancer imaging, particularly in positron emission tomography (PET) and single-photon emission computed tomography (SPECT) . BQ7859 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10788

CK3 peptide	Complement System	Cancer
CK3 peptide is an NRP-1 targeting peptide with the amino acid sequence CLKADKAKC. The CK3 peptide specifically binds to NRP-1 to target breast cancer cells. Single-photon emission computed tomography (SPECT) and near-infrared fluorescence (NIRF) imaging show significant accumulation of CK3 peptide in xenograft tumors in nude mice. CK3 peptide can be used for molecular imaging studies of breast cancer.

HY-P0036D

NOTA-Octreotide	Drug Derivative Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor Apoptosis	Cancer
NOTA‑Octreotide is a selective SSTR2‑targeting PET tracer. NOTA‑Octreotide binds specifically to SSTR2 and accumulates in SSTR2‑expressing tissues. NOTA‑Octreotide enables effective imaging of somatostatin receptor‑positive tumors in mice and shows high specific uptake in SSTR2‑expressing organs in healthy rats. NOTA-Octreotide can be used for PET imaging investigation of neuroendocrine tumors. .

HY-P11591

PDI2 PSMA-DOTA-PEI2	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
PDI2 (PSMA-DOTA-PEI2) is a prostate-specific membrane antigen (PSMA) ligand that acts as a tumor retention agent, renal uptake reducer, imaging agent and antitumor agent, applicable in SPECT diagnostic imaging and radiotheranostics. PDI2 specifically binds to PSMA on prostate cancer cells, enters cells via clathrin-dependent endocytosis, and exhibits higher tumor retention rate and lower renal uptake level. PDI2 is applicable in research related to prostate cancer and castration-resistant metastatic prostate cancer .

HY-P11415

GX1	Peptides	Cancer
GX1 is a tumor-homing peptide, and its amino acid sequence is CGNSNPKSC. GX1 can specifically target the vascular endothelial cells of gastric cancer and can be used as a specific imaging probe for gastric cancer angiogenesis .

HY-P11737

IPM-N001	Radionuclide-Drug Conjugates (RDCs) Carbonic Anhydrase	Cancer
IPM-N001 is a carbonic anhydrase IX (CAIX) ligand with a K_d value of <0.0337 nM for hCAIX. When radio-conjugated with ⁶⁸Ga, IPM-N001 serves as a CAIX-targeted radionuclide tracer. [ ⁶⁸Ga]Ga-IPM-N001 exhibits excellent tumor uptake and significantly improves the tumor-to-background ratio in PET/CT imaging studies using OS-RC-2 tumor-bearing mice. IPM-N001 can be used for the research of clear cell renal cell carcinoma .

HY-P11739

ZD2 peptide	Biochemical Assay Reagents	Cancer
ZD2 peptide is an EDB-FN-binding peptide with a K_d value of 11 μM. ZD2 peptide binds specifically to the EDB protein fragment of extradomain B fibronectin, a tumor microenvironment biomarker. ZD2 peptide can be conjugated to imaging agents. ZD2 peptide can be used for the research of cancer .

HY-P11590

WGYRGFYC	EGFR	Cancer
WGYRGFYC (WC8) is a selective HER2-targeting peptide that binds specifically to HER2 by mimicking the antigen-binding site of trastuzumab. The DOTA precursor of WGYRGFYC has a K_D of 61.20 nM for HER2. WGYRGFYC enables specific and highly sensitive detection of HER2 expression in HER2-positive breast cancer cells and tumor tissues, and monitors the dynamic downregulation of HER2 expression. WGYRGFYC rapidly distributes to target tissues and is efficiently cleared from non-target tissues via the kidneys, generating an ideal tumor-to-background ratio in imaging; it is a component of the PET radiotracer Ga-DOTA-WC8. WGYRGFYC exhibits no significant cytotoxicity in breast cancer cells, and can be used for non-invasive imaging diagnosis and therapeutic efficacy evaluation of HER2-positive breast cancer .

HY-P10989

NG2 binding peptide	Peptides	Cancer
NG2 binding peptide is a short peptide that specifically recognizes NG2 proteoglycan and can be obtained by phage screening technology. NG2 binding peptide interacts with NG2 binding sites to achieve precise targeting of tumor angiogenesis in vitro and in vivo. NG2 binding peptide exhibits significant homing ability in wild-type tumor-bearing mice, but has no localization effect in NG2 knockout mice. Due to the tissue specificity of NG2 expression, NG2 binding peptide can be used in scenarios such as tumor targeted therapy, drug delivery, and molecular imaging diagnosis .

HY-P3440A

NOTA-WL12	Drug Derivative PD-1/PD-L1	Cancer
NOTA-WL12 is a conjugate of WL12 (HY-P3440) (peptide targeting PD-L1) and NOTA (HY-134418) (chelate). NOTA-WL12 shows high binding affinity to the PD-L1 (K_D = 3.012 nM). NOTA-WL12 can be labeled with radioactive isotopes for tumor imaging .

HY-P11596

NOTA-Asp2-αvβ6L	Integrin	Cancer
NOTA-Asp2-αvβ6L is an integrin αvβ6 binder with selective accumulation in αvβ6-positive pancreatic cancer cells and tumors. NOTA-Asp2-αvβ6L can be used as a PET/CT tracer for imaging pancreatic ductal adenocarcinoma (PDAC) .

HY-P11618

10P3Me	Glycoprotein VI	Cancer
10P3Me is a Glypican-3 (GPC3)-targeting probe with a K_a of 93.8 nM for the human target. 10P3Me exhibits high binding affinity to GPC3, targets GPC3-positive cells, and serves as an agent for PET imaging. 10P3Me selectively accumulates in GPC3-positive tumor tissues, including subcutaneous xenograft models and orthotopic HepG2-LUC liver cancer models, to achieve precise localization of lesions .

HY-P11486

NOTA-RHAU18	Radionuclide-Drug Conjugates (RDCs) G-quadruplex DNA/RNA Synthesis Mitochondrial Metabolism	Cancer
NOTA-RHAU18 is a conjugate of the chelator NOTA and the peptide RHAU18. NOTA-RHAU18 can be used to synthesize the radiolabeled peptide probe [ ¹⁸F]AlF-NOTA-RHAU18. [ ¹⁸F]AlF-NOTA-RHAU18 targets mitochondrial DNA G4. [ ¹⁸F]AlF-NOTA-RHAU18 can be used to visualize and detect solid tumors in homozygous mice. [ ¹⁸F]AlF-NOTA-RHAU18 can also be used in PET imaging studies .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99289

Epratuzumab Antibody hLL 2; AMG-412	CD22	Inflammation/Immunology Cancer
Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases .

HY-P991577

DS-8895 DS-8895A	Ephrin Receptor	Cancer
DS-8895(DS-8895A) is an anti-EphA2 monoclonal antibody with specific binding to EphA2 receptors and EphA2-expressing cells. DS-8895, when conjugated with ⁸⁹Zr, ¹¹¹In, or ¹²⁵I, supports molecular imaging of EphA2 expression in xenograft models. DS-8895 allows noninvasive measurement of EphA2 expresssion in tumors in vivo. .

HY-P991319

TAB-004	Inhibitory Antibodies	Cancer
TAB-004 is a murine IgG1 monoclonal antibody that specifically binds to the tumor-associated hypoglycosylated mucin 1 (tMUC1), with high selectivity for human tMUC1. TAB-004 can be conjugated with Indocyanine green (ICG) (HY-D0711) for in vivo targeted imaging. TAB-004 can be used for the research of early detection, tumor progression monitoring and cancer stem cell targeting in breast cancer and pancreatic cancer.

HY-P992459

SGM-101 Antibody	ADC Antibody Transmembrane Glycoprotein	Cancer
SGM-101 Antibody is a chimeric monoclonal antibody targeting carcinoembryonic antigen (CEA). SGM-101 Antibody can serve as a tumor-specific fluorescent imaging probe after being covalently conjugated with the near-infrared fluorescent dye BM104 . SGM-101 Antibody accumulates in CEA-positive tumor tissues via antigen-antibody specific binding, and emits near-infrared fluorescence to enable imaging of tumor lesions. SGM-101 Antibody can be used in research related to gastric cancer, colorectal cancer, pancreatic cancer, non-small cell lung cancer, breast cancer, peritoneal carcinomatosis, and liver metastases .

HY-P992340

CTB006	Radionuclide-Drug Conjugates (RDCs) TNF Receptor	Cancer
CTB006 is a monoclonal antibody targeting a humanized chimeric recombinant anti-DR5. CTB006 specifically binds to and activates DR5, thereby inducing tumor cell apoptosis, inhibiting tumor growth and reducing tumor drug resistance. ¹⁷⁷Lu-radiolabeled CTB006 can deliver targeted radiotherapy to tumor cells; while ⁸⁹Zr- or ¹⁷⁷Lu-labeled CTB006 can serve as a PET/CT imaging agent for detecting DR5 expression levels in preclinical tumor models and screening cancers with DR5 overexpression. CTB006 can be applied to research related to gastrointestinal cancer, colorectal cancer and other solid tumors .

HY-P992339

cT84.66	Radionuclide-Drug Conjugates (RDCs)	Cancer
cT84.66 is a highly efficient tumor-targeting agent against carcinoembryonic antigen (CEA). cT84.66 engages in bivalent binding with CEA via variable region antigen-binding sites, enabling precise targeting of CEA-producing tumor cells for delivery of therapeutic radiation. cT84.66 exhibits high tumor uptake rate, rapid clearance rate, and excellent tumor-to-blood ratio. With dual functions as an imaging agent and an antibody-directed radiotherapy agent, cT84.66 is widely used in studies of colorectal cancer and metastatic CEA-positive malignancies .

HY-P992449

REGN2878 PRLR ADC antibody	ADC Antibody	Cancer
REGN2878 (PRLR ADC antibody) is a monoclonal antibody targeting the prolactin receptor (PRLR) and can block prolactin‑mediated activation of PRLR. REGN2878 exhibits an equilibrium dissociation constant (K_D) of 1.05 nM and an IC₅₀ of 0.344 nM for human PRLR. REGN2878 can be rapidly internalized and degraded in lysosomes by PRLR‑positive tumor cells, showing antigen‑specific binding and targeted enrichment properties. REGN2878 derivatives can be used as an immunoPET agent for antigen‑specific imaging of PRLR‑related tumors, and can also serve as a component of ADCs to exert anti‑tumor activity in breast cancer xenograft models. REGN2878 can be used in the research of breast cancer and prostate cancer. Isotype Comparison HY-P99001 .

HY-P992367

hIMB1636	TROP2	Cancer
hIMB1636 is a humanized monoclonal antibody targeting Trop2. By binding to the conformational Trop2 epitope, hIMB1636 regulates related signaling pathways, triggers lysosomal endocytosis, and further induces apoptosis, cell cycle arrest, and antibody-dependent cellular cytotoxicity. hIMB1636 effectively inhibits tumor cell proliferation, migration and in vivo tumor growth, and also exerts bystander killing effect and mediates long-term retention. hIMB1636 can be conjugated with NOTA/DOTA for radiolabeling to enable immuno-PET imaging, or prepared as hIMB1636-LDP-AE to significantly inhibit the growth of breast cancer and lung cancer xenografts .

HY-P992341

D8P1C1	MMP	Cancer
D8P1C1 is a high-affinity ADAM17 inhibitor (with a K_d of 180 pM targeting ADAM17-ECD) that reduces the shedding and phosphorylation of EGFR ligands. D8P1C1 inhibits cancer cell proliferation in vitro and tumor growth in xenograft models. ⁸⁹Zr-DFO-D8P1C1 radioimmunological PET imaging shows its substantial accumulation in ovarian tumor xenografts, serving as a platform for generating bispecific T-cell engager derivatives. D8P1C1 can be applied to research on related diseases including triple-negative breast cancer, various types of ovarian cancer, lung adenocarcinoma, glioma, and colon cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N6664

Gum arabic Arabic gum	Structural Classification Senegalia senegal (L.) Britton Polysaccharides Classification of Application Fields Leguminosae Other Diseases Plants Disease Research Fields Saccharides Source Classification	Environmental Pollutants Parasite Apoptosis PERK Transmembrane Glycoprotein
Gum Arabic is an orally active complex branched polysaccharide. Gum Arabic can be isolated from the Acacia senegal tree. Gum Arabic upregulates the expression of maturation markers (CD86, CD40, and CD54), promotes ERK1/2 phosphorylation, and inhibits Apoptosis. Gum Arabic exhibits antimalarial effects against Plasmodium berghei ANKA. Gum Arabic exhibits hepatoprotective, renal, and cardiovascular protective activities. Gum Arabic improves obesity. Gum Arabic is commonly used as a stabilizer and thickener. Gum Arabic can be used in the research of brain tumor imaging .

HY-N9459

2-Amino-2-deoxyglucose hydrochloride D-Glucosamine Hydrochloride	Structural Classification Microorganisms Classification of Application Fields Other Diseases Disease Research Fields Saccharides Source Classification	GLUT
2-Amino-2-deoxyglucose hydrochloride (D-Glucosamine Hydrochloride) is a glucose analog that is specifically recognized and transported by the cell membrane GLUT1. 2-Amino-2-deoxyglucose hydrochloride acts as a tumor-targeting ligand and a guiding molecule for the synthesis of prodrug conjugates, thus delivering drugs precisely to tumor cells. 2-Amino-2-deoxyglucose hydrochloride is applicable to diagnostic imaging and therapeutic efficacy monitoring of solid tumors and various cancers (e.g., breast cancer, glioblastoma). 2-Amino-2-deoxyglucose hydrochloride also helps bacteria resist lysozyme digestion by integrating into the non-N-acetylated residues of Streptococcus pneumoniae peptidoglycan. 2-Amino-2-deoxyglucose hydrochloride is used in studies on tumor metabolism and the exploration of bacterial drug resistance mechanisms .

Cat. No.	Product Name	Chemical Structure

HY-W752886

Estradiol 3-d3 (β-D-Glucuronide) sodium
Estradiol 3-d₃ (β-D-Glucuronide) sodium is the deuterium labeled Estradiol 3-(β-D-Glucuronide) sodium (HY-N7755). Estradiol 3-(β-D-Glucuronide) sodium is the glucuronic acid derivative of estradiol (HY-B0141). Estradiol 3-(β-D-Glucuronide) sodium is radiolabeled for use in tumor imaging and biodistribution studies .

HY-122607S

DPA-714-d10

DPA-714-d₁₀ is the deuterium labeled DPA-714 (HY-122607). DPA-714 is a high affinity translocator protein (TSPO) ligand (K_i=7 nM), which is designed with a fluorine atom in its structure, allowing labelling with fluorine -18 and in vivo imaging using positron emission tomography. ¹⁸FDPA-714 successfully evaluates for the specific imaging of inflammation in various models of neuroinflammation and in a brain tumor model.

Cat. No.	Product Name		Classification

HY-145746

Sulfo-Cy5 azide		Labeling and Fluorescence Imaging Azide
Sulfo-Cy5 azide is a near-infrared fluorescent probe with favorable click chemistry reactivity. Sulfo-Cy5 azide enables fluorescence imaging, tissue and cellular visualization of PD-L1 in tumors, and site-specific modification of anti-PD-L1 antibodies. Sulfo-Cy5 azide has been employed for RNA labeling and imaging. Sulfo-Cy5 azide can be conjugated to targeting agents for fluorescence imaging in atherosclerosis and breast cancer models (Ex/Em = 645/670 nm) .

HY-158067

Deferoxamine-DBCO DFO-DBCO		DBCO
Deferoxamine-DBCO is a bifunctional chelating agent. Deferoxamine-DBCO efficiently chelates with radioactive metals (such as ⁸⁹Zr) through the DFO structure to achieve radiolabeling. Deferoxamine-DBCO undergoes a metal-free Huisgen cycloaddition reaction with azide-containing biomolecules (such as siRNA, monoclonal antibodies) under bioorthogonal conditions through the DBCO structure to achieve targeted coupling. Deferoxamine-DBCO has efficient metal chelating ability and specific bioorthogonal reaction activity. Deferoxamine-DBCO can be used for targeted radioactive imaging studies of tumors .

HY-180447

Tz-Ph-PEG4-NH-DOTA		Tetrazine
Tz-Ph-PEG4-NH-DOTA (Compound 10) is a 1,2,4,5-tetrazine (Tz) derivative. Tz-Ph-PEG4-NH-DOTA can be used in PET imaging and tumor research .

HY-151704

ICG-alkyne		Alkynes
ICG-alkyne is a short-wave infrared (SWIR)-emitting cyanine fluorescent probe based on alkyne-derivatized indocyanine green. ICG-alkyne can undergo click chemistry reaction to conjugate with antibody molecules via binding to the azide groups introduced into antibodies. ICG-alkyne enables SWIR fluorescent molecular imaging of breast tumors in living mice. ICG-alkyne can be used in breast cancer-related research .

Cat. No.	Product Name		Classification

HY-N6664

Gum arabic Arabic gum		Emulsifiers Suspending Agents
Gum Arabic is an orally active complex branched polysaccharide. Gum Arabic can be isolated from the Acacia senegal tree. Gum Arabic upregulates the expression of maturation markers (CD86, CD40, and CD54), promotes ERK1/2 phosphorylation, and inhibits Apoptosis. Gum Arabic exhibits antimalarial effects against Plasmodium berghei ANKA. Gum Arabic exhibits hepatoprotective, renal, and cardiovascular protective activities. Gum Arabic improves obesity. Gum Arabic is commonly used as a stabilizer and thickener. Gum Arabic can be used in the research of brain tumor imaging .

HY-W440911

DSPE-PEG2000-Cy5		Pegylated Lipids Fluorescent Lipids
DSPE-PEG2000-Cy5 is a Cy5 (HY-D0821) fluorophore-labeled conjugate of distearoylphosphatidylethanolamine and polyethylene glycol, as well as a liposome component. The Cy5 fluorophore is commonly used for labeling proteins and nucleic acids in imaging, flow cytometry and genomic applications. DSPE-PEG2000-Cy5 supports cell membrane modification, in vivo tumor targeting research and long-term in vivo circulation of its liposomal formulations (Ex/Em=633/670 nm) .

HY-W342664

2'-Deoxy-2'-fluoro-5-iodouridine FIRU		Nucleoside Analogs Uridine
2'-Deoxy-2'-fluoro-5-iodouridine (FIRU) is a nucleoside analog. When labeled with ¹²³I, 2'-Deoxy-2'-fluoro-5-iodouridine accumulates highly selectively in tumors expressing the HSV1-tk gene. Radiolabeled 2'-Deoxy-2'-fluoro-5-iodouridine enables imaging of adenovirus-mediated HSV1-tk suicide gene transfer .

HY-160066

SYL3C aptamer sodium		Aptamers
SYL3C aptamer sodium is a DNA aptamer that targets epithelial cell adhesion molecule (EpCAM) on the surface of cancer cells. SYL3C aptamer sodium targets a variety of human cancer cell lines including MDA-MB-231, Kato III, HT-29, T47D and SW480. The K_d values of SYL3C aptamer sodium against breast cancer cell line MDA-MB-231 and gastric cancer cell line Kato III are 38 nM and 67 nM, respectively. SYL3C aptamer sodium possesses stability, high binding affinity and selectivity, and can be used for targeted cancer cell imaging and circulating tumor cell detection .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

tumor imaging.

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Natural
Products